Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 870

1.

Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.

Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D.

J Nucl Med. 2018 Jun;59(6):909-914. doi: 10.2967/jnumed.117.199737. Epub 2017 Oct 12.

PMID:
29025985
2.

Distribution of corticotropin-releasing factor (CRF) receptor binding in the mouse brain using a new, high-affinity radioligand, [125 I]-PD-Sauvagine.

Tan LA, Vaughan JM, Perrin MH, Rivier JE, Sawchenko PE.

J Comp Neurol. 2017 Dec 15;525(18):3840-3864. doi: 10.1002/cne.24307. Epub 2017 Sep 13.

PMID:
28842924
3.

Prospective Clinical Applications of CRF Peptide Antagonists.

Rivier JE.

Curr Mol Pharmacol. 2017;10(4):264-269. doi: 10.2174/1874467210666170110112914. Review.

PMID:
28103781
4.

A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin.

Menting JG, Gajewiak J, MacRaild CA, Chou DH, Disotuar MM, Smith NA, Miller C, Erchegyi J, Rivier JE, Olivera BM, Forbes BE, Smith BJ, Norton RS, Safavi-Hemami H, Lawrence MC.

Nat Struct Mol Biol. 2016 Oct;23(10):916-920. doi: 10.1038/nsmb.3292. Epub 2016 Sep 12.

PMID:
27617429
5.

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers.

Reubi JC, Waser B, Mäcke H, Rivier J.

J Nucl Med. 2017 Feb;58(2):300-306. doi: 10.2967/jnumed.116.177733. Epub 2016 Aug 25.

6.

Solid-state NMR sequential assignment of the β-endorphin peptide in its amyloid form.

Seuring C, Gath J, Verasdonck J, Cadalbert R, Rivier J, Böckmann A, Meier BH, Riek R.

Biomol NMR Assign. 2016 Oct;10(2):259-68. doi: 10.1007/s12104-016-9681-z. Epub 2016 May 10.

PMID:
27165576
7.

Structural Basis for the Inhibition of Voltage-gated Sodium Channels by Conotoxin μO§-GVIIJ.

Green BR, Gajewiak J, Chhabra S, Skalicky JJ, Zhang MM, Rivier JE, Bulaj G, Olivera BM, Yoshikami D, Norton RS.

J Biol Chem. 2016 Mar 25;291(13):7205-20. doi: 10.1074/jbc.M115.697672. Epub 2016 Jan 27.

8.

Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).

Erchegyi J, Wang L, Gulyas J, Samant M, Perrin MH, Lewis K, Miller C, Vaughan J, Donaldson C, Fischer W, Low W, Yakabi S, Karasawa H, Taché Y, Rivier C, Rivier J.

J Med Chem. 2016 Feb 11;59(3):854-66. doi: 10.1021/acs.jmedchem.5b00926. Epub 2016 Feb 3.

9.

Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.

Perrin MH, Tan LA, Vaughan JM, Lewis KA, Donaldson CJ, Miller C, Erchegyi J, Rivier JE, Sawchenko PE.

J Pharmacol Exp Ther. 2015 May;353(2):307-17. doi: 10.1124/jpet.114.222307. Epub 2015 Mar 3.

10.

Α- and β-subunit composition of voltage-gated sodium channels investigated with μ-conotoxins and the recently discovered μO§-conotoxin GVIIJ.

Wilson MJ, Zhang MM, Gajewiak J, Azam L, Rivier JE, Olivera BM, Yoshikami D.

J Neurophysiol. 2015 Apr 1;113(7):2289-301. doi: 10.1152/jn.01004.2014. Epub 2015 Jan 28.

11.

Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice.

Mulak A, Larauche M, Biraud M, Million M, Rivier J, Taché Y.

Peptides. 2015 Jan;63:71-80. doi: 10.1016/j.peptides.2014.10.013. Epub 2014 Nov 5.

12.

Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior.

Karasawa H, Yakabi S, Wang L, Stengel A, Rivier J, Taché Y.

Am J Physiol Regul Integr Comp Physiol. 2014 Oct 1;307(7):R793-801. doi: 10.1152/ajpregu.00248.2014. Epub 2014 Jul 16.

13.

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA.

J Nucl Med. 2014 Aug;55(8):1248-52. doi: 10.2967/jnumed.114.138834. Epub 2014 Jun 24.

14.

Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli.

Jappelli R, Perrin MH, Lewis KA, Vaughan JM, Tzitzilonis C, Rivier JE, Vale WW, Riek R.

PLoS One. 2014 Jan 17;9(1):e84013. doi: 10.1371/journal.pone.0084013. eCollection 2014.

15.

Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.

Rivier JE, Rivier CL.

Front Neuroendocrinol. 2014 Apr;35(2):161-70. doi: 10.1016/j.yfrne.2013.10.006. Epub 2013 Nov 20. Review.

16.

Anxiolytic-like effects of antisauvagine-30 in mice are not mediated by CRF2 receptors.

Zorrilla EP, Roberts AJ, Rivier JE, Koob GF.

PLoS One. 2013 Aug 28;8(8):e63942. doi: 10.1371/journal.pone.0063942. eCollection 2013.

17.

Key role of CRF in the skin stress response system.

Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, Rivier J.

Endocr Rev. 2013 Dec;34(6):827-84. doi: 10.1210/er.2012-1092. Epub 2013 Aug 12. Review.

18.

CRH receptor antagonism reverses the effect of social subordination upon central GABAA receptor binding in estradiol-treated ovariectomized female rhesus monkeys.

Michopoulos V, Embree M, Reding K, Sanchez MM, Toufexis D, Votaw JR, Voll RJ, Goodman MM, Rivier J, Wilson ME, Berga SL.

Neuroscience. 2013 Oct 10;250:300-8. doi: 10.1016/j.neuroscience.2013.07.002. Epub 2013 Jul 12.

19.

Mammalian neuronal sodium channel blocker μ-conotoxin BuIIIB has a structured N-terminus that influences potency.

Kuang Z, Zhang MM, Gupta K, Gajewiak J, Gulyas J, Balaram P, Rivier JE, Olivera BM, Yoshikami D, Bulaj G, Norton RS.

ACS Chem Biol. 2013;8(6):1344-51. doi: 10.1021/cb300674x. Epub 2013 Apr 16.

20.

Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.

Vaughan JM, Donaldson CJ, Fischer WH, Perrin MH, Rivier JE, Sawchenko PE, Vale WW.

Endocrinology. 2013 Apr;154(4):1553-64. doi: 10.1210/en.2012-2011. Epub 2013 Mar 14.

21.

Pharmacological fractionation of tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons by μ-conotoxins.

Zhang MM, Wilson MJ, Gajewiak J, Rivier JE, Bulaj G, Olivera BM, Yoshikami D.

Br J Pharmacol. 2013 May;169(1):102-14. doi: 10.1111/bph.12119.

22.

Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Stengel A, Rivier J, Taché Y.

Peptides. 2013 Apr;42:70-7. doi: 10.1016/j.peptides.2012.12.022. Epub 2012 Dec 31. Review.

23.

Co-expression of Na(V)β subunits alters the kinetics of inhibition of voltage-gated sodium channels by pore-blocking μ-conotoxins.

Zhang MM, Wilson MJ, Azam L, Gajewiak J, Rivier JE, Bulaj G, Olivera BM, Yoshikami D.

Br J Pharmacol. 2013 Apr;168(7):1597-610. doi: 10.1111/bph.12051.

25.

Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.

Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1876-85. doi: 10.1007/s00259-012-2231-8. Epub 2012 Aug 29.

PMID:
22926735
26.

Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC.

J Nucl Med. 2012 Sep;53(9):1481-9. doi: 10.2967/jnumed.112.102764. Epub 2012 Jul 31.

27.

Characterization of two neuronal subclasses through constellation pharmacology.

Teichert RW, Raghuraman S, Memon T, Cox JL, Foulkes T, Rivier JE, Olivera BM.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12758-63. doi: 10.1073/pnas.1209759109. Epub 2012 Jul 9.

28.

CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α.

Overman EL, Rivier JE, Moeser AJ.

PLoS One. 2012;7(6):e39935. doi: 10.1371/journal.pone.0039935. Epub 2012 Jun 29.

29.

Wylie Vale: neuroendocrine master.

Montminy M, Lee KF, Rivier JE, Rivier C, Reichlin S.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3604-5. doi: 10.1073/pnas.1201696109. Epub 2012 Feb 21. No abstract available.

30.

Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.

Chatenet D, Cescato R, Waser B, Erchegyi J, Rivier JE, Reubi JC.

EJNMMI Res. 2011 Sep 2;1(1):21. doi: 10.1186/2191-219X-1-21.

31.

Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA.

Khoo KK, Wilson MJ, Smith BJ, Zhang MM, Gulyas J, Yoshikami D, Rivier JE, Bulaj G, Norton RS.

J Med Chem. 2011 Nov 10;54(21):7558-66. doi: 10.1021/jm200839a. Epub 2011 Oct 12.

32.

First clinical evidence that imaging with somatostatin receptor antagonists is feasible.

Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, Maecke HR, Weber WA.

J Nucl Med. 2011 Sep;52(9):1412-7. doi: 10.2967/jnumed.111.088922. Epub 2011 Aug 18.

33.

N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.

Erchegyi J, Cescato R, Waser B, Rivier JE, Reubi JC.

J Med Chem. 2011 Sep 8;54(17):5981-7. doi: 10.1021/jm200307v. Epub 2011 Aug 16.

PMID:
21806016
34.

Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2.

Stengel A, Goebel-Stengel M, Wang L, Shaikh A, Lambrecht NW, Rivier J, Taché Y.

Am J Physiol Gastrointest Liver Physiol. 2011 Aug;301(2):G239-48. doi: 10.1152/ajpgi.00018.2011. Epub 2011 Jun 2.

35.

Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress.

Fekete EM, Zhao Y, Szücs A, Sabino V, Cottone P, Rivier J, Vale WW, Koob GF, Zorrilla EP.

Br J Pharmacol. 2011 Dec;164(8):1959-75. doi: 10.1111/j.1476-5381.2011.01512.x.

36.

Central administration of pan-somatostatin agonist ODT8-SST prevents abdominal surgery-induced inhibition of circulating ghrelin, food intake and gastric emptying in rats.

Stengel A, Goebel-Stengel M, Wang L, Luckey A, Hu E, Rivier J, Taché Y.

Neurogastroenterol Motil. 2011 Jul;23(7):e294-308. doi: 10.1111/j.1365-2982.2011.01721.x. Epub 2011 May 13.

37.

Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice.

Stengel A, Goebel-Stengel M, Wang L, Larauche M, Rivier J, Taché Y.

Neurogastroenterol Motil. 2011 Jun;23(6):e223-36. doi: 10.1111/j.1365-2982.2011.01706.x.

38.

CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice.

Wang L, Million M, Rivier J, Rivier C, Craft N, Stenzel-Poore MP, Taché Y.

PLoS One. 2011 Feb 16;6(2):e16377. doi: 10.1371/journal.pone.0016377.

39.

Chronic injection of pansomatostatin agonist ODT8-SST differentially modulates food intake and decreases body weight gain in lean and diet-induced obese rats.

Stengel A, Coskun T, Goebel-Stengel M, Craft LS, Alsina-Fernandez J, Wang L, Rivier J, Taché Y.

Regul Pept. 2011 Apr 11;167(2-3):201-8. doi: 10.1016/j.regpep.2011.01.006. Epub 2011 Feb 17.

40.

Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents.

Gourcerol G, Wu SV, Yuan PQ, Pham H, Miampamba M, Larauche M, Sanders P, Amano T, Mulak A, Im E, Pothoulakis C, Rivier J, Taché Y, Million M.

Gastroenterology. 2011 May;140(5):1586-96.e6. doi: 10.1053/j.gastro.2011.01.039. Epub 2011 Jan 26.

41.

Increased ghrelin sensitivity and calorie consumption in subordinate monkeys is affected by short-term astressin B administration.

Michopoulos V, Loucks T, Berga SL, Rivier J, Wilson ME.

Endocrine. 2010 Oct;38(2):227-34. doi: 10.1007/s12020-010-9378-5. Epub 2010 Jul 17. Erratum in: Endocrine. 2010 Dec;38(3):417.

42.

Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice.

Wang L, Stengel A, Goebel M, Martinez V, Gourcerol G, Rivier J, Taché Y.

Peptides. 2011 Jan;32(1):51-9. doi: 10.1016/j.peptides.2010.10.017. Epub 2010 Oct 20.

43.

Activation of brain somatostatin 2 receptors stimulates feeding in mice: analysis of food intake microstructure.

Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Mönnikes H, Taché Y.

Physiol Behav. 2010 Dec 2;101(5):614-22. doi: 10.1016/j.physbeh.2010.09.009. Epub 2010 Sep 17.

44.

NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.

Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R.

J Biol Chem. 2010 Dec 3;285(49):38580-9. doi: 10.1074/jbc.M110.121897. Epub 2010 Sep 15.

45.

Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats.

Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Monnikes H, Tache Y.

J Physiol Pharmacol. 2010 Aug;61(4):399-407.

46.

Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats.

Goebel M, Stengel A, Wang L, Coskun T, Alsina-Fernandez J, Rivier J, Taché Y.

Brain Res. 2010 Sep 10;1351:150-64. doi: 10.1016/j.brainres.2010.07.024. Epub 2010 Jul 15.

47.

Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in rats.

Stengel A, Coskun T, Goebel M, Wang L, Craft L, Alsina-Fernandez J, Rivier J, Taché Y.

Endocrinology. 2010 Sep;151(9):4224-35. doi: 10.1210/en.2010-0195. Epub 2010 Jul 7.

48.

Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.

Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1551-8. doi: 10.1007/s00259-010-1445-x. Epub 2010 Apr 16.

49.

Early weaning stress impairs development of mucosal barrier function in the porcine intestine.

Smith F, Clark JE, Overman BL, Tozel CC, Huang JH, Rivier JE, Blikslager AT, Moeser AJ.

Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G352-63. doi: 10.1152/ajpgi.00081.2009. Epub 2009 Nov 19.

50.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, Schonbrunn A.

Mol Endocrinol. 2010 Jan;24(1):240-9. doi: 10.1210/me.2009-0321. Epub 2009 Nov 12.

Supplemental Content

Loading ...
Support Center